BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31778258)

  • 1. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
    Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
    Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
    Park SA; Kim LK; Park HM; Kim HJ; Heo TH
    Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euxanthone inhibits glycolysis and triggers mitochondria-mediated apoptosis by targeting hexokinase 2 in epithelial ovarian cancer.
    Zou J; Wang Y; Liu M; Huang X; Zheng W; Gao Q; Wang H
    Cell Biochem Funct; 2018 Aug; 36(6):303-311. PubMed ID: 29984416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
    Shimbo A; Kajiyama H; Tamauchi S; Yoshikawa N; Ikeda Y; Nishino K; Suzuki S; Niimi K; Sakata J; Kikkawa F
    Oncol Rep; 2019 Dec; 42(6):2323-2332. PubMed ID: 31578579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl‑2/Bax and GSK3β/β‑catenin signaling pathways.
    Zhang H; Dong R; Zhang P; Wang Y
    Oncol Rep; 2019 May; 41(5):3069-3079. PubMed ID: 30896826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
    Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ
    Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
    Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
    Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of 4.1N in epithelial ovarian cancer results in EMT and matrix-detached cell death resistance.
    Wang D; Zhang L; Hu A; Wang Y; Liu Y; Yang J; Du N; An X; Wu C; Liu C
    Protein Cell; 2021 Feb; 12(2):107-127. PubMed ID: 32448967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
    Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
    Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
    Saini U; Naidu S; ElNaggar AC; Bid HK; Wallbillich JJ; Bixel K; Bolyard C; Suarez AA; Kaur B; Kuppusamy P; Hays J; Goodfellow PJ; Cohn DE; Selvendiran K
    Oncogene; 2017 Jan; 36(2):168-181. PubMed ID: 27292260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
    Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
    Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
    Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer.
    Standing D; Dandawate P; Gunewardena S; Covarrubias-Zambrano O; Roby KF; Khabele D; Jewell A; Tawfik O; Bossmann SH; Godwin AK; Weir SJ; Jensen RA; Anant S
    Cell Death Dis; 2024 May; 15(5):362. PubMed ID: 38796478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.